Michael Yee (Allogene open house Credit: Jeff Rumans)

Hold the phone, bio­phar­ma: FDA-im­posed clin­i­cal holds are on the rise

Are clin­i­cal holds on the rise? Ac­cord­ing to one analy­sis, signs point to yes, and one field, in par­tic­u­lar, is prov­ing a like­ly cul­prit.

Jef­feries’ Michael Yee came out with a note Sun­day de­tail­ing the sharp rise of FDA-im­posed holds over the last 18 to 24 months fol­low­ing a decade of rel­a­tive­ly lit­tle move­ment on that trend. And if things con­tin­ue un­abat­ed, 2022 has the po­ten­tial to eclipse even last year’s mark.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.